Skyrizi Alternatives Compared
| Skyrizi (risankizumab) | Otezla (apremilast) | Humira (adalimumab) |
|
|---|
| Skyrizi (risankizumab) | Otezla (apremilast) | Humira (adalimumab) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Skyrizi is an interleukin inhibitor that may be used to treat adults with plaque psoriasis, psoriatic arthritis, Crohn's disease, or ulcerative colitis (UC). The usual dosage is 150mg every 12 weeks... View more |
Prescription only
Otezla is a PDE4 inhibitor that may be used to treat adults with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s Disease. It may also be used to treat plaque psoriasis... View more |
Prescription only
Humira is a TNF-alfa inhibitor that may be used to treat a wide range of different inflammatory conditions, such as Rheumatoid Arthritis, psoriasis, ankylosing spondylitis, Crohn's disease, and... View more |
Related suggestions Popular comparisons
|
|||||||||||||||||||||||
| More about Skyrizi (risankizumab) | More about Otezla (apremilast) | More about Humira (adalimumab) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Skyrizi has an average rating of 7.9 out of 10 from a total of 56 ratings on Drugs.com. 73% of reviewers reported a positive effect, while 14% reported a negative effect. |
Otezla has an average rating of 5.2 out of 10 from a total of 439 ratings on Drugs.com. 35% of reviewers reported a positive effect, while 40% reported a negative effect. |
Humira has an average rating of 6.4 out of 10 from a total of 698 ratings on Drugs.com. 55% of reviewers reported a positive effect, while 31% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
|
View all Skyrizi side effects |
View all Otezla side effects |
View all Humira side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
N/A |
N/A |
|||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Skyrizi prices |
View all Otezla prices |
View all Humira prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
|
N/A |
N/A |
Other adalimumab brands include: Abrilada, Amjevita, Cyltezo, Hadlima, Hulio, Hyrimoz, Idacio, Simlandi, Yuflyma, Yusimry View more | ||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
672 hours |
9 hours |
480 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 184 drugs are known to interact with Skyrizi:
|
A total of 107 drugs are known to interact with Otezla:
|
A total of 549 drugs are known to interact with Humira:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
April 23, 2019 |
March 21, 2014 |
December 31, 2002 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.